Skip to main content
Fig. 1 | Molecular Cancer

Fig. 1

From: Mutation of lysine-specific demethylase 5 is associated with enhanced tumor immunity and favorable outcomes in pan-cancer immune checkpoint blockade

Fig. 1

KDM5 mutation as an independent biomarker for favorable outcomes in pan-cancer immune checkpoint blockade. (A) Pooled Kaplan–Meier survival analysis stratified by KDM5A/C mutation status in 2943 patients with 12 distinct tumor types treated with ICIs. (B) Comparison of objective response rate in patients with KDM5A/C mutation and patients with KDM5A/C non-mutation. (C-F) Association between KDM5A mutation and OS (C), KDM5A mutation and ORR (D), KDM5C mutation and OS (E), KDM5C mutation and ORR (F) in patients treated with ICIs. (G-H) Univariate (G) and multivariate (H) Cox analysis of the association between KDM5A/C mutation and OS in 2943 patients treated with ICIs. CI, confidence interval; CR, complete response; HR, hazard ratio; ICI, immune checkpoint inhibitor; ORR, objective response rate; OS, overall survival; PD, progressive disease; PR, partial response; SD, stable disease

Back to article page

Molecular Cancer

ISSN: 1476-4598